Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan

Journal of Managed Care Pharmacy

Volumn 14, Issue 3, 2008, Pages 291-301

  D'Souza, Anna O ^a   Smith, Michael J ^b   Miller, Lesley Ann ^c   Doyle, Joseph ^d   Ariely, Rinat ^d  

^a XCENDA   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOXATE; HYOSCYAMINE; OXYBUTYNIN; PROPANTHELINE BROMIDE; TOLTERODINE; TROSPIUM CHLORIDE;

ADULT; ARTICLE; BIVARIATE ANALYSIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENDED RELEASE FORMULATION; FEMALE; HEALTH CARE PLANNING; HUMAN; IMMEDIATE RELEASE FORMULATION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; REIMBURSEMENT; RETROSPECTIVE STUDY; XEROSTOMIA;

EID: 44049092119     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.3.291     Document Type: Article

References (40)